Kite Pharma (KITE) Receives FDA Approval for Yescarta Label Update

The U.S. Food and Drug Administration approved a label update for Yescarta (axicabtagene ciloleucel), a CAR-T therapy from Kite Pharma (KITE). The change expands indications to includeregorafenib-refractory or -resistant gastrointestinal stromal tumors (GIST), adding treatment options for a rare and aggressive cancer subtype. The FDA's decision reflects a review of clinical trials that demonstrated the therapy's safety and efficacy in this new population. The updated label is effective immediately, enabling earlier approval and broader use of Yescarta in GIST cases where standard treatments have failed.